Pacira Biosciences Inc. (PCRX)

38.22
NASDAQ : Health Technology
Prev Close 38.94
Day Low/High 38.04 / 39.43
52 Wk Low/High 35.07 / 55.00
Avg Volume 502.00K
Exchange NASDAQ
Shares Outstanding 41.63M
Market Cap 1.62B
P/E Ratio 204.95
Div & Yield N.A. (N.A)
Pacira BioSciences Reports Second Quarter 2019 Financial Results And Business Update

Pacira BioSciences Reports Second Quarter 2019 Financial Results And Business Update

-- Total revenues increased 22% over prior year to $102.6 million in second quarter -- -- Conference call today at 8:30 a.

First Week Of February 2020 Options Trading For Pacira BioSciences (PCRX)

First Week Of February 2020 Options Trading For Pacira BioSciences (PCRX)

Investors in Pacira BioSciences Inc saw new options become available this week, for the February 2020 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

PCRX: Insiders Vs. Shorts

PCRX: Insiders Vs. Shorts

The most recent short interest data was recently released for the 03/29/2019 settlement date, and Pacira Pharmaceuticals Inc. is one of the most shorted stocks of the Russell 3000, based on 7.50 "days to cover" versus the median component at 4.78.

First Week Of PCRX November 15th Options Trading

First Week Of PCRX November 15th Options Trading

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the November 15th expiration.

PCRX: Insiders Vs. Shorts

PCRX: Insiders Vs. Shorts

The most recent short interest data was recently released for the 10/31/2018 settlement date, and Pacira Pharmaceuticals Inc. is one of the most shorted stocks of the Russell 3000, based on 5.07 "days to cover" versus the median component at 4.44.

PCRX Crosses Above Average Analyst Target

PCRX Crosses Above Average Analyst Target

In recent trading, shares of Pacira Pharmaceuticals Inc. have crossed above the average analyst 12-month target price of $46.31, changing hands for $47.40/share.

Pacira Pharmaceuticals Reaches Analyst Target Price

Pacira Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Pacira Pharmaceuticals Inc. have crossed above the average analyst 12-month target price of $46.08, changing hands for $47.15/share.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANDE, BPI, CORE, ECHO, EPAY, FRD, HTBI, LAWS, MCY, MEDP, NMFC, NTES, PCRX, SCHL, SLG, SU, SWIR Downgrades: AKAM, AXU, DFRG, FFWM, IAG, IVC, MHK, RGNX, SRE, TARO, TWNK, UNFI, VECO Initiations: CGBD, SMHI, WTTR Read on to get TheStreet Quant Ratings' detailed report:

First Week Of February 2019 Options Trading For Pacira Pharmaceuticals (PCRX)

First Week Of February 2019 Options Trading For Pacira Pharmaceuticals (PCRX)

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the February 2019 expiration.

MEDNAX National Medical Group And Pacira Pharmaceuticals Launch National Enhanced Recovery After Cesarean Surgery (ERACS™) Collaborative To Minimize Opioid Use

MEDNAX National Medical Group And Pacira Pharmaceuticals Launch National Enhanced Recovery After Cesarean Surgery (ERACS™) Collaborative To Minimize Opioid Use

MEDNAX, Inc. (NYSE:MD), the national health solutions partner specializing in anesthesiology, neonatology, maternal-fetal medicine, other pediatric services, radiology and management services, is pleased to announce that it has partnered with Pacira...

Interesting PCRX Put And Call Options For June 15th

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the June 15th expiration.

University Of Tennessee Medical Center At Knoxville, Pacira Pharmaceuticals, And CQ-Insights Announce Collaboration To Minimize Opioid Use After Hernia Surgery

University Of Tennessee Medical Center At Knoxville, Pacira Pharmaceuticals, And CQ-Insights Announce Collaboration To Minimize Opioid Use After Hernia Surgery

Continuous quality improvement project aims to optimize patient outcomes after hernia repair

Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee To Review SNDA For EXPAREL® As A Nerve Block For Regional Analgesia

Pacira Pharmaceuticals Stock Trading Halted; FDA Advisory Committee To Review SNDA For EXPAREL® As A Nerve Block For Regional Analgesia

Anesthetic and Analgesic Drug Products Advisory Committee Meeting February 14-15

First Week of March 16th Options Trading For Pacira Pharmaceuticals (PCRX)

First Week of March 16th Options Trading For Pacira Pharmaceuticals (PCRX)

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the March 16th expiration.

WellStar Health System And Pacira Pharmaceuticals Announce Partnership To Minimize Opioid Use And Standardize Outcomes Across Surgical Procedures

WellStar Health System And Pacira Pharmaceuticals Announce Partnership To Minimize Opioid Use And Standardize Outcomes Across Surgical Procedures

Agreement will focus on designing and deploying best practice enhanced recovery protocols across therapeutic areas in 11 Georgia-based hospitals

First Week Of PCRX August 2018 Options Trading

First Week Of PCRX August 2018 Options Trading

Investors in Pacira Pharmaceuticals Inc. saw new options begin trading this week, for the August 2018 expiration.

Illinois Surgical Quality Improvement Collaborative And Pacira Pharmaceuticals, Inc. Announce Collaboration To Minimize Opioid Exposure For Postsurgical Patients

Illinois Surgical Quality Improvement Collaborative And Pacira Pharmaceuticals, Inc. Announce Collaboration To Minimize Opioid Exposure For Postsurgical Patients

Collaboration will develop and distribute evidence-based strategies, education and resources to reduce the overprescribing and optimize the use of opioids across 56 Illinois hospitals

Pacira Announces Promotions Of Scott Braunstein, MD, To Chief Operating Officer And Richard Scranton, MD, To Chief Scientific Officer

Pacira Announces Promotions Of Scott Braunstein, MD, To Chief Operating Officer And Richard Scranton, MD, To Chief Scientific Officer

Expanded roles reflect key accomplishments and demonstrated leadership

TheStreet Quant Rating: C (Hold)